C3J Therapeutics Announces Issuance of U.S. Patent Covering Synthetic Bacteriophage April 2, 2019 C3J’s pending merger with AmpliPhi Biosciences, which will create a clinical-stage phage leader, is on track to close in May 2019 LOS ANGELES, Calif., April 2, 2019 — C3J Therapeutics, Inc. (C3J) a private clinical stage biotechnology company focused on … Continued
AmpliPhi Biosciences and C3J Therapeutics Agree to Merge January 4, 2019 Transaction to result in NYSE American-listed company focused on development of precisely-targeted bacteriophage therapeutics Merger combines AmpliPhi’s extensive phage library and Phase 1/2-ready asset with C3J’s expertise in synthetic phage and broad preclinical pipeline $10 million to be invested by … Continued
C3J Therapeutics Bolsters Antimicrobial R&D Program; Acquires Engineered Bacteriophage Assets from Synthetic Genomics February 28, 2018 LOS ANGELES, and LA JOLLA, CALIF., February 28, 2018 — C3J Therapeutics, Inc., (C3J) a private biotechnology company focused on the development of novel targeted antimicrobials, and Synthetic Genomics, Inc., (SGI) a leader in designing and programming biology for desired … Continued